Lipid Therapeutics GmbH
π©πͺGermany
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
Phase 2
- Conditions
- Ulcerative ColitisLarge IntestineDiarrheaAbdominal Pain
- Interventions
- Drug: placebo
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Lipid Therapeutics GmbH
- Target Recruit Count
- 156
- Registration Number
- NCT01011322
- Locations
- π©πͺ
University Clinics des Saarlandes, Homburg/Saar, Saarland, Germany
π©πͺUniversitaetsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
π©πͺCity Hospital Braunschweig, Braunschweig, Lower Saxony, Germany
Β© Copyright 2025. All Rights Reserved by MedPath